Figure S4 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Ioannis Vathiotis(Yale University), David L. Rimm(Yale University), Sébastien Guillaume(Institut Jules Bordet), Thazin Nwe Aung(Yale University), Prajan Divakar(Dartmouth College), Lajos Pusztai(Yale University), Sung‐Bae Kim(Ulsan College), Nadia Harbeck(Breast Center), George Fountzilas(Hellenic Cooperative Oncology Group), Henry Gómez, Christos Sotiriou(Université Libre de Bruxelles), Aileen I. Fernandez(Yale University), Vesal Yaghoobi(Yale University), Jens Huober(University of St.Gallen), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Sarah Warren(Nanostring Technologies (United States)), Myrto Moutafi(University General Hospital Attikon), Saba Shafi(Ministry of Education of the People's Republic of China), Qing Tao, Yingbo Wang, Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Konstantinos N. Syrigos(National and Kapodistrian University of Athens), Sarra El-Abed
Cited by 0
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k